Teva Pharmaceutical Indus 주식 (NYSE: TEVA)

에 대한 최신 뉴스 Teva Pharmaceutical Indus (NYSE:TEVA) 주식

Teva Pharmaceutical Indus

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Analysts expect Ford Motor Co. (NYSE: F) to post quarterly earnings at 33 cents per share on revenue of $43.25 billion after the closing bell. Ford shares fell 0.7% to $10.09 in after-hours trading.

Equities

News

Markets

Tech

General

ADBE

ADSK

AMZN

AVGO

GOOGL

MSFT

NTRA

NVDA

SBUX

TEVA

TSLA

최근 13F 공시에 따르면 억만장자 투자자 스탠리 드러켄밀러의 가족 투자사인 듀케인(Duquesne)은 브로드컴(NASDAQ:AVGO) 주식을 전량 매각하는 동시에 주요 기술 기업에 대한 투자를 늘렸다.

스탠리 드러켄밀러의 4분기 포트폴리오: 브로드컴 처분, 테슬라·아마존 등 대형 기술주에 대규모 투자

Uber Weride

Mid Cap

Movers

Trading Ideas

AXSM

CRSP

MKGAF

MKKGY

RXRX

SWTX

VNET

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 위라이드(NASDAQ:WRD)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:NVDA)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.

위라이드, 크리스퍼 및 진DX 등 지난주 최대 상승한 10개의 중형주 (2월 10일-2월 14일)

Record-Breaking Market Losses: Nvidia Tops The List Of The 10 Largest Wipeouts In History

Large Cap

DECK

MANH

SMCI

이들 12개 대형주들은 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 맨해튼 어소시에이츠(NASDAQ:MANH)의 주식은 회사가 2025 회계연도에 대한 부진한 가이던스를 발표한 후 27.92% 급락했다. 애널리스트들이 가격 예측을 하향 조정한 것도 영향을 미쳤다.

엔비디아, 테바 파마 및 UPS 등 지난주 하락한 12개의 대형주 (1월 27일-1월 31일)

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Industries Ltd

TEVA PHARM INDUS LTD ORD by Teva Pharmaceutical Industries Ltd.

TEVANO SYS HLDGS INC by Tevano Systems Holdings Inc.

Tevano Systems Holdings Inc

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully&nbsp;upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the "Notes"). The principal amount of the offering was increased from the previously announced offering size of $2,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings (i) to fund the announced tender offers (collectively, the "Tender Offer") to purchase, for cash, its 3.150% Senior Notes due 2026, 4.750% Sustainability-Linked Senior Notes due 2027, 3.750% Sustainability-Linked Senior Notes due 2027, 7.875% Sustainability-Linked Senior Notes due 2029, 7.375% Sustainability-Linked Senior Notes due 2029 and 8.125% Sustainability-Linked Senior Notes due 2031&nbsp;(as it may be amended prior to expiration thereof), (ii) to pay fees and expenses in connection therewith and (iii) to the extent of any remaining proceeds, the repayment of outstanding debt upon maturity, tender offer or earlier redemption. Net proceeds may be temporarily invested pending application for their stated purpose.
The Notes consist of (i) Teva Pharmaceutical Finance Netherlands II B.V's ("Teva Finance II") €1,000,000,000 aggregate principal amount of 4.125% EUR-denominated Senior Notes maturing in 2031, (ii) Teva Pharmaceutical Finance Netherlands III B.V.'s ("Teva Finance III") $500,000,000 aggregate principal amount of 6.000% USD-denominated Senior Notes maturing in 2032 and (iii) Teva Pharmaceutical Finance Netherlands IV B.V.'s ("Teva Finance IV" and, together with Teva Finance II and Teva Finance III, the "Issuers") $700,000,000 aggregate principal amount of 5.750% USD-denominated Senior Notes maturing in 2030.
The settlement of the Notes is expected to occur on or about May 28, 2025, subject to customary closing conditions. The settlement of the Notes will satisfy the financing condition to the Tender Offer.

Offerings

Teva Pharmaceutical Industries Announces It Upsized Its Offering From $2B And Priced ~$2.3B Of Its Senior Notes

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it has commenced tender offers (the "Offers") to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) (the "Total Maximum Amount") of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
<ul>
<li>USD 3.150% Senior Notes due 2026, CUSIP 88167AAE1 / ISIN US88167AAE10 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Pool 1 Notes");</li>
<li>USD 4.750% Sustainability-Linked Senior Notes due 2027, CUSIP 88167AAP6 / ISIN US88167AAP66 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Priority 2 Notes");</li>
<li>EUR 3.750% Sustainability-Linked Senior Notes due 2027, Common Code 240660709 / ISIN XS2406607098 (Registered), issued by Teva Pharmaceutical Finance Netherlands II B.V. (the "Priority 3 Notes" and together with the Priority 2 Notes, the "Pool 2 Notes");</li>
<li>USD 7.875% Sustainability-Linked Senior Notes due 2029, CUSIP 88167AAS0 / ISIN US88167AAS06 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Priority 4 Notes");</li>
<li>EUR 7.375% Sustainability-Linked Senior Notes due 2029, Common Code 259280443 / ISIN XS2592804434 (Registered), issued by Teva Pharmaceutical Finance Netherlands II B.V. (the "Priority 5 Notes"); and</li>
<li>USD 8.125% Sustainability-Linked Senior Notes due 2031, CUSIP 88167AAR2 / ISIN US88167AAR23 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Priority 6 Notes," and together with the Priority 4 Notes and the Priority 5 Notes, the "Pool 3 Notes," and the Pool 3 Notes, together with the Pool 1 Notes and the Pool 2 Notes, the "Notes").</li>
</ul>

Buybacks

Teva Launches $2 Billion Bond Buyback to Cut Debt Across Multiple Note Series

Teva Pharmaceuticals (NYSE and TASE: TEVA)&nbsp;today announced that Moody's Investor Services ("Moody's") has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive.

Analyst Ratings

Teva Pharmaceuticals Announced That Moody's Investor Services Has Raised The Company's Corporate Credit Rating To Ba1, Outlook Stable From Ba2, Outlook Positive

WIIM

Teva Pharmaceuticals shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $21 to $23.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Guggenheim cut Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) price target from $55 to $45. Guggenheim analyst Debjit Chattopadhyay maintained a Buy rating. Intellia Therapeutics shares closed at $8.12 on Friday. <a href="https://www.benzinga.com/quote/NTLA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised the price target for Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) from $12 to $14. Canaccord Genuity analyst Maria Ripps maintained a Buy rating. Nexxen International shares closed at $11.54 on Friday. <a href="https://www.benzinga.com/quote/NEXN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) price target from $35 to $28. Goldman Sachs analyst Stephen Laszczyk downgraded the stock from Buy to Neutral. Warner Music shares closed at $27.36 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/WMG/analyst-ratings">view this stock</a>.</li>
<li>HC Wainwright &amp; Co slashed the price target for Ocugen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) from $8 to $7. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintained a Buy rating. Ocugen shares closed at $0.67 on Friday. <a href="https://www.benzinga.com/quote/OCGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham slashed the price target for Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) from $19 to $14. Needham analyst Joseph Stringer maintained a Buy rating. Vir Biotechnology shares closed at $5.09 on Friday. <a href="https://www.benzinga.com/quote/VIR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised Teva Pharmaceutical Industries Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NASDAQ">TEVA</a>) price target from $21 to $23. JP Morgan analyst Chris Schott upgraded the stock from Neutral to Overweight. Teva Pharmaceutical shares settled at $16.93 on Friday. <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies increased Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) price target from $226 to $303. Jefferies analyst David Katz upgraded the stock from Hold to Buy. Marriott shares closed at $257.97 on Friday. <a href="https://www.benzinga.com/quote/MAR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barrington Research raised DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) price target from $20 to $21. Barrington Research analyst Michael Petusky maintained an Outperform rating. Dentsply Sirona shares closed at $15.81 on Friday.  <a href="https://www.benzinga.com/quote/XRAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt slashed the price target for TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) from $4.5 to $4. Rosenblatt analyst Chris Brendler maintained a Buy rating. TeraWulf shares settled at $3.01 on Friday. <a href="https://www.benzinga.com/quote/WULF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital raised Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) price target from $14 to $27. D. Boral Capital analyst Jason Kolbert maintained a Buy rating. Medicus Pharma shares closed at $4.69 on Friday. <a href="https://www.benzinga.com/quote/MDCX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MAR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="612" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-1024x612.png" alt="" class="wp-image-911954" style="width:591px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-1024x612.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127.png 1130w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

MDCX

NEXN

NTLA

OCGN

WULF

XRAY

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Keybanc analyst Steve Barger upgraded Federal Signal Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) from Sector Weight to Overweight and announced a $110 price target. Federal Signal shares closed at $89.56 on Friday. <a href="https://www.benzinga.com/quote/fss/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Argus Research analyst John Staszak upgraded the rating for Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) from Hold to Buy and announced a $40 price target. Wayfair shares closed at $32.79 on Friday. <a href="https://www.benzinga.com/quote/W/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Peter Heckmann upgraded ACI Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIW#NASDAQ">ACIW</a>) from Neutral to Buy and maintained the price target of $60. ACI Worldwide shares closed at $46.56 on Friday. <a href="https://www.benzinga.com/quote/ACIW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst David Katz upgraded the rating for Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) from Hold to Buy and raised the price target from $226 to $303. Marriott International shares closed at $257.97 on Friday. <a href="https://www.benzinga.com/quote/MAR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Chris Schott upgraded Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) from Neutral to Overweight and raised the price target from $21 to $23. Teva Pharmaceutical shares closed at $16.93 on Friday. <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying W stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-1024x584.png" alt="" class="wp-image-911884" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

ACIW

This Wayfair Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

JP Morgan analyst Chris Schott upgrades Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) from Neutral to Overweight and raises the price target from $21 to $23.

Price Target

JP Morgan Upgrades Teva Pharmaceutical Indus to Overweight, Raises Price Target to $23

B of A Securities analyst Jason Gerberry maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy and raises the price target from $20 to $22.

B of A Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $22

Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) stock is trading higher on Wednesday after the company&#8217;s first-quarter 2025 financial results. <a href="https://www.benzinga.com/pressreleases/25/05/g45248070/teva-reports-ninth-consecutive-quarter-of-growth-in-q1-2025-with-key-innovative-medicines-growing-" target="_blank" rel="noreferrer noopener">Here are the details</a>.
Teva reported revenue of $3.89 billion, up 5% year-over-year, missing analyst estimates of $4.00 billion, according to&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
The increase was driven by higher revenues from Austedo in the U.S. segment. Austedo&#8217;s worldwide revenues were $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024.
<ul>
<li>U.S. Austedo revenues increased by 40% to $396 million, mainly due to volume growth, including the approval of Austedo XR, a once-daily pill, in May 2024.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday" rel="noreferrer noopener">Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?</a>
Ajovy&#8217;s global revenues were $139 million in Q1 2025, an increase of 26% in local currency terms compared to Q1 2024.
<ul>
<li>US Ajovy&nbsp;revenues were $53 million, an increase of 18% compared to the first quarter of 2024, mainly due to volume growth.</li>
<li>Uzedy&#8217;s global revenues are $39 million in Q1 2025.</li>
<li>The generics business grew across all regions—it increased by 5% in the U.S., 1% in Europe, and 2% in International Markets, all in local currency terms, compared to Q1 2024.</li>
</ul>
The company reported first-quarter adjusted earnings of 52 cents per share, beating <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimates of 48 cents per share</a>.
Gross profit margin&nbsp;was 48.2% in the first quarter of 2025, compared to 46.4% a year ago, and adjusted gross profit margin&nbsp;was 52.8% compared to 51.4% in the first quarter of 2024.
<ul>
<li>The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to a favorable mix of products, primarily driven by higher revenues from Austedo, partially offset by a negative impact from foreign exchange rate movements, including hedging effects.</li>
</ul>
Richard Francis, Teva&#8217;s president and CEO, said, &#8220;Now entering the Acceleration Phase of our Pivot to Growth Strategy, we have a clear roadmap to continue Teva&#8217;s transformation into a leading biopharmaceutical company with an expected 30% operating margin, and today have announced ~$700 million net savings by 2027. We&#8217;re accelerating innovative growth and strengthening our generics business, while streamlining our operations, sharpening our business, and optimizing processes. With these results, we are revising our 2025 outlook and reaffirming our 2027 targets.&#8221;
Guidance: Teva Pharmaceutical raises fiscal 2025 adjusted earnings per share from $2.35-$2.65 to $2.45-$2.65 versus the consensus of $2.55.
The generics player narrows 2025 sales guidance from $16.8 billion-$17.4 billion to $16.8 billion-$17.2 billion compared to the consensus of $17.24 billion.
The company said the outlook is based on the existing tariff and trade environment, and does not reflect any policy shifts, including pharmaceutical sector tariffs, that could impact business.
The company increased the Austedo 2025 sales outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.
Teva reaffirmed sales forecasts of $600 million for Ajovy, about $160 million for Uzedy, and approximately $370 million for Copaxone.
Teva also raised operating income guidance from&nbsp;$4.1 billion-$4.6 billion to $4.3 billion-$4.6 billion, with adjusted EBITDA of $4.7 billion-$5.0 billion from $4.5 billion-$5.0 billion.
Price Action: TEVA stock is up 8.2% at $17.48 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45254006/bunge-q1-eps-beats-expectations-cites-tariff-driven-demand-shifts-as-tailwind" target="_blank" rel="noreferrer noopener">Bunge Q1 EPS Beats Expectations, CEO Credits &#8216;Tariff-Related Timing Shifts&#8217; As Tailwind</a></li>
</ul>
Photo: Shutterstock

Biotech

Guidance

Health Care

Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum

Teva Pharmaceutical Industries shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and raised its FY25 adjusted EPS guidance.

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) raises FY2025 Adj EPS guidance from $2.35-$2.65 to $2.45-$2.65 vs $2.55 analyst estimate. Narrows FY2025 sales outlook from $16.80 billion-$17.40 billion to $16.80 billion-$17.20 billion vs $17.24 billion estimate.

Teva Pharmaceutical Indus Raises FY2025 Adj EPS Guidance From $2.35-$2.65 To $2.45-$2.65 vs $2.55 Est; Narrows FY2025 Sales Guidance From $16.80B-$17.40B To $16.80B-$17.20B vs $17.24B Est

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.48 by 8.33 percent. This is a 8.33 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $3.89 billion which missed the analyst consensus estimate of $4.00 billion by 2.78 percent. This is a 1.89 percent increase over sales of $3.82 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Teva Pharmaceutical Indus Q1 Adj. EPS $0.52 Beats $0.48 Estimate, Sales $3.89B Miss $4.00B Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Neurocrine Biosciences Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) stock is trading higher on Tuesday after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45206088/neurocrine-biosciences-reports-first-quarter-2025-financial-results-and-reaffirms-2025-financial-g" rel="noreferrer noopener">first-quarter 2025 earnings</a>.
The company on Monday reported adjusted EPS of 70 cents, lower than the $1.20 reported a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of 54 cents</a>.
Neurocrine reported sales of $572.6 million compared to $515.3 million a year ago, missing the&nbsp;consensus of $559.3 million.
Ingrezza&#8217;s first-quarter 2025 net product sales were&nbsp;$545 million, representing an 8% year-over-year growth, driven by underlying patient demand, including record new patient starts and improved gross-to-net dynamics.
<ul>
<li>Expanded formulary access for Ingrezza significantly improved coverage to include two-thirds of tardive dyskinesia (TD) and Huntington&#8217;s disease Medicare beneficiaries.</li>
<li>William Blair writes, &#8220;Ingrezza sales for the quarter were more resilient than investors had feared given Part D formulary utilization and Teva Pharmaceutical Industries Ltd&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Austedo competition.&#8221;</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44818760/neurocrine-biosciences-positive-crenessity-physician-survey-turns-this-analyst-bullish" rel="noreferrer noopener">Neurocrine Biosciences&#8217; Positive Crenessity Physician Survey Turns This Analyst Bullish</a>
Crenessity first-quarter net product sales were&nbsp;$14.5 million&nbsp;and included 413 total patient enrollment start forms, reflecting strong initial patient demand with approximately 70% reimbursement coverage for dispensed scripts.
Guidance:&nbsp;Neurocrine Biosciences reaffirms its <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43569079/why-is-neurocrine-biosciences-stock-trading-lower-on-friday" rel="noreferrer noopener">2025 Ingrezza sales guidance</a> of $2.5 billion-$2.6 billion.
Despite headwinds, Ingrezza sales &#8220;avoided a big miss,&#8221; William Blair analyst Myles R. Minter said in a Tuesday research note.
Minter views Ingrezza as &#8220;the gold-standard pharmacotherapy for TD, given its once-daily dosing, no need for long dose titration intervals, and lack of a suicidality and depression FDA black-box warning.&#8221; In addition, the company boasts 14 years of potential future patent protection. 
&#8220;We also view the beat from Crenessity as indicative of a strong sales effort, and although early, we are impressed by the early launch metrics and interest in the orphan disease therapy,&#8221; Minter added.
William Blair <a target="_blank" href="https://www.benzinga.com/quote/NBIX/analyst-ratings" rel="noreferrer noopener">maintains the Outperform rating</a>.
Other analyst reaction:
<ul>
<li>Needham maintains Neurocrine Biosciences with a Buy, raising the price target from $138 to $139.</li>
<li>Canaccord Genuity maintains Neurocrin with a Buy, raising the price target from $158 to $160.</li>
<li>UBS keeps the Buy rating for Neurocrine, raising the price target from $137 to $152.</li>
<li>BMO Capital maintains Neurocrine with a Market Perform, raising the price target from $96 to $115.</li>
<li>Guggenheim maintains Neurocrine with a Buy, raising the price target from $155 to $165.</li>
</ul>
Price Action: NBIX stock is up 14% at $125.07&nbsp;at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45221957/pasithea-therapeutics-drug-shows-tumor-reduction-in-pancreatic-cancer-strong-early-trial-results" target="_blank" rel="noreferrer noopener">Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results</a></li>
</ul>

Analyst Color

NBIX

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target

The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Alvotech&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Stelara (ustekinumab)</a>.
As of April 30, 2025, Selarsdi is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn&#8217;s disease, and ulcerative colitis.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43910567/sanofi-teva-unveil-new-detailed-data-for-duvakitug-study-supporting-overall-efficacy-for-common-inflammatory-bowel-disease" rel="noreferrer noopener">Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease</a>
&#8220;Teva&#8217;s recent launch of two biosimilars – SELARSDI and EPYSQLI – coupled with a rich pipeline of assets expected to launch over the next few years, position Teva to establish a strong leadership position in the growing landscape of biosimilars and to drive growth for the company as it embarks on the next phase of its strategy,&#8221; said Thomas Rainey, senior vice president, U.S. Biosimilars at Teva.
Approved <a target="_blank" href="https://www.globenewswire.com/news-release/2025/05/05/3073922/0/en/Teva-and-Alvotech-Announce-FDA-Approval-of-Interchangeability-for-SELARSDI-ustekinumab-aekn-with-Stelara-ustekinumab.html" rel="noreferrer noopener">presentations</a> of Selarsdi are 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection, 45 mg/0.5 mL in a single-dose vial for subcutaneous injection and 130 mg/26 mL in a single-dose vial for intravenous infusion.
Alvotech developed and produces Selarsdi using Sp2/0 cells and a continuous perfusion process, which are the same type of host cell line and process used in the production of Stelara.
In August 2020, Teva and Alvotech entered into a strategic partnership to exclusively commercialize five Alvotech biosimilar product candidates. In July 2023, the partnership was extended to include two additional biosimilars and new presentations of two previously partnered products.
<ul>
<li>Alvotech manages development and manufacturing, while Teva is responsible for exclusive commercialization in the U.S., leveraging its experience and extensive sales and marketing infrastructure.</li>
<li>Two biosimilars developed under the Teva &#8211; Alvotech partnership have been granted FDA approval with interchangeability, including Selarsdi. In February 2024, the FDA approved Simlandi (adalimumab-ryvk), the first high-concentration, a citrate-free interchangeable biosimilar to AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Humira&nbsp;(adaliumumab), which was launched in the U.S. in May 2024.</li>
</ul>
Biologics License Applications (BLAs) for three additional biosimilar candidates developed by Alvotech in partnership with Teva have been accepted for review by the FDA:
<ul>
<li>AVT05, a proposed biosimilar for Johnson &amp; Johnson&#8217;s Simponi (golimumab) and Simponi Aria (golimumab).</li>
<li>AVT06, a proposed biosimilar for Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Eylea (aflibercept).</li>
<li>Biosimilar User Fee Act (BsUFA) goal dates for approval for these BLAs are in Q4 2025.</li>
</ul>
Price Action: TEVA stock is up 2.10% at $16.53 and ALVO stock is up 0.67% at $8.22 at the last on check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45179379/motorolas-resilient-orders-solid-margins-drive-analyst-confidence-despite-tariff-risks" target="_blank" rel="noreferrer noopener">Motorola&#8217;s Resilient Orders, Solid Margins Drive Analyst Confidence Despite Tariff Risks</a></li>
</ul>
Photo: Shutterstock

ABBV

REGN

Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?

TEVA stock has given up its prior gain. Teva Pharmaceuticals shares were trading higher after the company announced FDA Approval for SELARSDI Injection as an interchangeable with the reference biologic Stelara

GPUS: 190% &#x7C; <a href="https://www.benzinga.com//node/45189955">Hyperscale Data Announces Prelim. Q1 Revenue Surpassing $25M; Sees FY25 Revenue $115M-$125M</a>
&nbsp;
TEVA: 7% &#x7C; <a href="https://www.benzinga.com//node/45190906">Teva Pharmaceuticals shares are trading higher after the company announced FDA Approval for SELARSDI Injection as an interchangeable with the reference biologic Stelara</a>
&nbsp;
WEN: 2% &#x7C; <a href="https://www.benzinga.com//node/45189966">Stephens &amp; Co. Reiterates Equal-Weight on Wendy's, Maintains $14 Price Target</a>

GPUS

Market-Moving News for May 5th

Teva Pharmaceuticals shares are trading higher after the company announced FDA Approval for SELARSDI Injection as an interchangeable with the reference biologic Stelara

<ul>
<li>The U.S. FDA has approved SELARSDI&#x2122; (ustekinumab-aekn) as interchangeable with the reference biologic Stelara&#xAE; (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025</li>
<li>SELARSDI is approved for all indications matching the reference product</li>
<li>SELARSDI is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older, and the treatment of adult patients with moderately to severely active Crohn's disease and ulcerative colitis</li>
</ul>
PARSIPPANY, N.J. and REYKJAVIK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI&#x2122; (ustekinumab-aekn) injection as interchangeable with the reference biologic Stelara&#xAE; (ustekinumab). As of April 30, 2025, SELARSDI is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis.

Teva Pharma And Alvotech Announce FDA Approval For SELARSDI Injection As Interchangeable With Reference Biologic Stelara

Teva Pharmaceutical Indus's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) short percent of float has fallen 6.34% since its last report. The company recently reported that it has 30.34 million shares sold short, which is 2.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Teva Pharmaceutical Indus Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746043230_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teva Pharmaceutical Indus has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teva Pharmaceutical Indus's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Teva Pharmaceutical Indus's peer group average for short interest as a percentage of float is 3.75%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About Teva Pharmaceutical Indus?

Press Releases

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

Financing

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

Bonds

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Comments

Teva Pharmaceutical Indus

뉴스

에 대한 최신 뉴스 Teva Pharmaceutical Indus (NYSE:TEVA) 주식

화요일, 2월 18, 2025

일요일, 2월 16, 2025

일요일, 2월 02, 2025

수요일, 12월 25, 2024

월요일, 12월 23, 2024

일요일, 12월 22, 2024

수요일, 12월 18, 2024

일요일, 5월 12, 2024

수요일, 5월 08, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌